| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
4,932 | 6,025 | 7,973 | 9,361 | 8,527 |
|
Cost of Revenue
|
-4,257 | -5,705 | -9,135 | -9,446 | -7,216 |
|
Gross Profit
|
675 | 320 | -1,162 | -85 | 1,311 |
| Selling, General and Administrative Expenses
|
-4,460 | -5,376 | -10,293 | -11,652 | -15,663 |
|
Research and Development Expenses
|
-99 | -21 | -1,169 | -2,559 | -2,564 |
| Depreciation, Amortization and Depletion
|
-148 | -284 | -336 | -379 | -496 |
| Other Income/Expense, Operating
|
-846 | -977 | -1,757 | -2,336 | -3,184 |
|
Operating Income/Expenses
|
-5,553 | -6,658 | -13,555 | -16,926 | -21,907 |
|
Total Operating Profit/Loss
|
-4,878 | -6,338 | -14,717 | -17,011 | -20,596 |
| Total Net Finance Income/Expense
|
-1,319 | -1,312 | 10 | -1 | 61 |
| Net Investment Income
|
1,874 | 500 | 2,678 | 3,934 | 2,921 |
| Irregular Income/Expenses
|
-55 | -55 | 0 | -- | -- |
|
Other Income/Expense, Non-Operating
|
-1,068 | -1,675 | -3,153 | -2,531 | 0 |
|
Non-Operating Income/Expenses, Total
|
-568 | -2,542 | -465 | 1,402 | 2,982 |
|
Pretax Income
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
|
Net Income from Continuing Operations
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
|
Net Income after Non-Controlling/Minority Interests
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
|
Net Income Available to Common Stockholders
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
|
Diluted Net Income Available to Common Stockholders
|
-5,446 | -8,880 | -15,182 | -15,609 | -17,614 |
| Basic EPS
|
-1.29 | -2.60 | -9.00 | -13.00 | -16.00 |
| Diluted EPS
|
-1.29 | -2.60 | -9.00 | -13.00 | -16.21 |
|
Basic Weighted Average Shares Outstanding
|
4,404.1500 | 3,424.8800 | 1,677.0860 | 1,167.7870 | 1,086.8480 |
|
Diluted Weighted Average Shares Outstanding
|
4,404.1500 | 3,424.8800 | 1,677.0860 | 1,297.7870 | 1,086.8480 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
-4,127 | -7,568 | -15,192 | -15,608 | -17,675 |
|
EBITDA
|
-3,966 | -7,284 | -14,856 | -15,229 | -17,179 |
|
Normalized EBITDA
|
-6,295 | -7,907 | -17,165 | -19,543 | -18,955 |
|
Normalized Income
|
-7,775 | -9,503 | -17,491 | -17,011 | -20,596 |
|
Total Unusual Items
|
-2,329 | -623 | -2,309 | -4,314 | -1,776 |
12/31/2022 - 9/26/2019
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade